Seems almost as if Oncolix is putting out PRs to placate shareholders while the total silence continues regarding the mid dose cohort My guess is those clinicals have not turned out well or havent moved forward. So talk about new products beginning to enter the narrative Bait & switch? These penny stock companies like Oncolix need to come clean with shareholders. Poor judgement